-
Small Cell SMASHERS Fireside Chat with Dr. Misty Shields
This special edition of the Small Cell SMASHERS features Misty Shields, MD, PhD, as a guest instead of her usual role as host. Dr. Shields is a thoracic medical oncologist, assistant professor of...
IN THE SPOTLIGHT
-
Biggest News from Berlin: Research Highlights from ESMO
Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With approximately 30,000... -
Explaining BiTE® Therapy
A bi-specific T-cell engager (BiTE®) is a new type of engineered molecule used for the treatment of cancer. These molecules harness and activate T-cells, which are involved in the... -
The Future of Lung Cancer Starts Here
For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested $55+ million in more than 200 research projects... -
SCLC Virtual Meetup
SCLC patients/survivors - Join us the 3rd Wednesday of every month to c onnect with others who share common experiences and build your community. Register in advance for this... -
Small Cell SMASHERS Fireside Chat with Dr. Trudy Oliver
In November, Trudy Oliver, PhD, professor of pharmacology and cancer biology at Duke University School of Medicine and Duke Cancer Institute, discussed the origins of small cell... -
Celebrating Progress in Lung Cancer: From Detection to Survivorship
Over the past twenty years, lung cancer research and care have entered a new era. One filled with hope, innovation, and progress that is transforming what it means to face a lung... -
Small Cell SMASHERS Fireside Chat: Dr. Toby Campbell
In this Facebook Live on Tuesday, October 14, Toby Campbell, MD, MS, thoracic medical oncologist and chief of palliative care at the University of Wisconsin Health, discussed... -
FDA Approves First Maintenance Treatment for ES-SCLC
On October 2, 2025, the US Food and Drug Administration (FDA) announced the approval of the combination treatment of lurbinectedin ( Zepzelca ®) plus atezolizumab ( Tecentriq ®) as... -
Small Cell SMASHERS Fireside Chat: Who's Up Next?
Small Cell SMASHERS Fireside Chat with Dr. Trudy Oliver Join us for a Facebook Live on Tuesday, November 25, with Trudy Oliver, PhD, professor of pharmacology and cancer biology at...
Circulating Tumor Cells May Guide Use of Tarlatamab in Small Cell Lung Cancer
Molecular Partners: First human images from targeting radiotherapy
New Lung Cancer Study Findings Have Been Reported by Researchers at Sivas Cumhuriyet University (Relationship Between Metabolic Parameters and Asphericity Derived from 18F-FDG PET/CT and...
New Lung Cancer Study Findings Have Been Reported by Researchers at Sivas Cumhuriyet University (Relationship Between Metabolic Parameters and Asphericity Derived from 18F-FDG PET/CT and...
Markey Cancer Center using new treatment for lung cancer
Durvalumab Cost-Effectiveness in LS-SCLC Under Review
Clinical Trial: A multicentre observational registry study of chemoradiotherapy followed by durvalumab in limited stage small cell lung cancer (Japan)
Clinical Trial: A multicentre observational registry study of chemoradiotherapy followed by durvalumab in limited stage small cell lung cancer (Japan)
Factors associated with longer brain metastasis-free survival in limited-disease small-cell lung cancer who underwent concurrent chemoradiotherapy, a retrospective analysis
Factors associated with longer brain metastasis-free survival in limited-disease small-cell lung cancer who underwent concurrent chemoradiotherapy, a retrospective analysis
University of Kentucky's Markey Cancer Center treats first patient in US with new lung cancer therapy
University of Kentucky's Markey Cancer Center treats first patient in US with new lung cancer therapy
Markey Cancer Center treats 1st patient in US with new lung cancer therapy
Safety evaluation of tarlatamab: A pharmacovigilance study based on the FAERS database
The Future of Lung Cancer Starts Here
The Future of Lung Cancer Starts Here
For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested $55+ million in more than 200 research projects, helping to build a robust pipeline of discoveries in early detection, treatment innovation, and health equity.Once again, LUNGevity is ready to open our annual grant cycle in 2026 with five research programs designed to address the most pressing challenges in lung cancer care. In addition, these grants ensure the…
Biggest News from Berlin: Research Highlights from ESMO
Biggest News from Berlin: Research Highlights from ESMO
Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With approximately 30,000 attendees from over 100 countries, this meeting gathered an international audience of clinicians, researchers, patient advocates, and representatives from the healthcare industry to discuss cutting-edge cancer research and share practice-changing clinical trial data. We saw data from studies that aim to build upon…
Small Cell SMASHERS Fireside Chat with Dr. Misty Shields
Small Cell SMASHERS Fireside Chat with Dr. Misty Shields
This special edition of the Small Cell SMASHERS features Misty Shields, MD, PhD, as a guest instead of her usual role as host. Dr. Shields is a thoracic medical oncologist, assistant professor of clinical medicine, adjunct assistant professor of medical and molecular genetics, and associate member of experimental and developmental therapeutics at Indiana University School of Medicine and Indiana University Health Physicians. Dr. Shields discusses her American Society of Clinical Oncology (…
Small Cell SMASHERS Fireside Chat with Dr. Trudy Oliver
Small Cell SMASHERS Fireside Chat with Dr. Trudy Oliver
In November, Trudy Oliver, PhD, professor of pharmacology and cancer biology at Duke University School of Medicine and Duke Cancer Institute, discussed the origins of small cell lung cancer (SCLC) and its impact on plasticity.Moderated by Dr. Misty Shields, Indiana University School of Medicine, and LUNGevity’s Ann Fish-Steagall, SVP of Patient Services and Health Care Delivery, this monthly virtual series highlights the latest discoveries and breakthroughs for SCLC.
Explaining BiTE® Therapy
Explaining BiTE® Therapy
A bi-specific T-cell engager (BiTE®) is a new type of engineered molecule used for the treatment of cancer. These molecules harness and activate T-cells, which are involved in the body’s immune response, to attack tumor cells. There is currently one FDA-approved BiTE® therapy treatment for targeting small cell lung cancer (SCLC).The video below was created to give you clear, easy-to-understand information about bi-specific T-cell engagers, so you can feel more informed and prepared as you…
Celebrating Progress in Lung Cancer: From Detection to Survivorship
Celebrating Progress in Lung Cancer: From Detection to Survivorship
Over the past twenty years, lung cancer research and care have entered a new era. One filled with hope, innovation, and progress that is transforming what it means to face a lung cancer diagnosis. From groundbreaking early detection efforts to life-extending treatments, each step forward represents years of collaboration between researchers, patients, and others in the lung cancer community.Today, LUNGevity celebrates five exciting areas of progress that highlight the incredible strides made…
Veteran Voices: Surgery to Survivorship at the VA
Veteran Voices: Surgery to Survivorship at the VA
Last November, Michael O’Donnell was at the Dallas VA during Lung Cancer Awareness Month. It’s where he receives treatment for his lung cancer, but on this specific day, he was joined by LUNGevity staff to talk with veterans about screening.“My job was easy. I was at a table with Kristi Griffith [LUNGevity’s Survivorship Navigator] so that I could answer questions as someone who uses the VA to get treated for lung cancer,” says Michael. Michael is a veteran of the Vietnam War and uses the…
Small Cell SMASHERS Fireside Chat: Dr. Toby Campbell
Small Cell SMASHERS Fireside Chat: Dr. Toby Campbell
In this Facebook Live on Tuesday, October 14, Toby Campbell, MD, MS, thoracic medical oncologist and chief of palliative care at the University of Wisconsin Health, discussed palliative care in small cell lung cancer.Moderated by Misty Shields, MD, PhD, IU Health, and LUNGevity’s Ann Fish-Steagall, RN, BSN, SVP of Patient Services and Health Care Delivery, the monthly Small Cell SMASHERS series highlights the latest discoveries and breakthroughs for SCLC.
FDA Approves First Maintenance Treatment for ES-SCLC
FDA Approves First Maintenance Treatment for ES-SCLC
On October 2, 2025, the US Food and Drug Administration (FDA) announced the approval of the combination treatment of lurbinectedin (Zepzelca®) plus atezolizumab (Tecentriq®) as the first maintenance (ongoing) therapy for patients with extensive-stage small cell lung cancer (ES-SCLC). This approval is for patients who are currently benefiting from initial treatments, such as atezolizumab or atezolizumab plus chemotherapy. Atezolizumab is an immunotherapy that blocks the PD-L1 protein…
Small Cell Lung Cancer: Not Small Anymore
Small Cell Lung Cancer: Not Small Anymore
Read time: 3 minutes.Small cell lung cancer (SCLC) research continues to progress at an unprecedented rate. Exciting news emerged from the 2025 World Congress on Lung Cancer, with six studies showing how innovative therapies have the potential to give people with lung cancer better outcomes and longer survival than ever before.After decades with little treatment progress, it was remarkable to see an entire session dedicated to the treatment of newly diagnosed extensive-stage SCLC (ES-SCLC) (…
Small Cell SMASHERS Fireside Chat: Dr. Sonam Puri
Small Cell SMASHERS Fireside Chat: Dr. Sonam Puri
In this Facebook Live from September 30, Sonam Puri, MD, Department of Thoracic Oncology at H. Lee Moffitt Cancer Center, discusses the importance of real-world data for treating small cell lung cancer.Moderated by Misty Shields, MD, PhD, IU Health, and LUNGevity’s Ann Fish-Steagall, RN, BSN, SVP of Patient Services and Health Care Delivery, the monthly Small Cell SMASHERS series highlights the latest discoveries and breakthroughs for SCLC.
Small Cell SMASHERS Fireside Chat: Kim Lowery Walker
Small Cell SMASHERS Fireside Chat: Kim Lowery Walker
In this Facebook Live from August 22, we learned about integrative medicine from Kim Lowery Walker, MBA, LCSW, Integrative Psycho-Oncology Program Manager and oncology therapist at Inova Peterson Life with Cancer.Moderated by Misty Shields, MD, PhD, IU Health, and LUNGevity’s Ann Fish-Steagall, RN, BSN, SVP of Patient Services and Health Care Delivery, the monthly Small Cell SMASHERS series highlights the latest discoveries and breakthroughs for SCLC.
6 Tips for Managing Scanxiety
6 Tips for Managing Scanxiety
Read time: 4 minutes.Scanxiety is a term used for the anxiety someone feels as a medical exam, like an MRI or CT scan, approaches. It can come with feelings of dread or worry, as well as “what if” thoughts focused on receiving bad news, like the return or growth of a cancerous tumor. Scanxiety can be intense and intrusive, and you might find it difficult to focus on other thoughts or tasks. Many people, especially those who did not experience anxiety prior to their diagnosis, might feel…
Why Do Some People Who Have Never Smoked Get Lung Cancer?
Why Do Some People Who Have Never Smoked Get Lung Cancer?
As tobacco use has declined in recent years, we have seen a new demographic of lung cancer patients emerge. Lung cancer in individuals who have never smoked (LCINS) is becoming more common. These people are often younger women with no history of tobacco exposure.Researchers are working to understand the needs of this growing population by identifying other risk factors for lung cancer, such as family history and environmental exposures. They are also studying the molecular underpinnings of this…
Panelists Discuss New Advances from ASCO 2025
Panelists Discuss New Advances from ASCO 2025
The publication OncLive convened a panel of experts to break down the SCLC news from the ASCO conference held in June 2025. Panelists discussed strategies for treating limited-stage (LS-SCLC) and extensive-stage (ES-SCLC) small cell lung cancer, including:Integration of durvalumab in LS-SCLCNew first-line chemoimmunotherapy regimens in ES-SCLCMaintenance approaches such as atezolizumab plus lurbinectedin and durvalumab plus tarlatamab (DeLLphi-305)The promising future role of agents including T…
2025 ASCO: Highlights of Lung Cancer Research
2025 ASCO: Highlights of Lung Cancer Research
The annual meeting of the American Society of Clinical Oncology (ASCO) once again brought together nearly 50,000 members of the oncology community. From May 30 – June 2, researchers, oncologists, and patient advocates had first-hand access to the latest cancer research news. The theme for the 2025 ASCO conference was “Driving Knowledge to Action: Building a Better Future.” This theme was represented through several presentations during the conference that showcased how the cancer…
Small Cell SMASHERS Fireside Chat: Drs. Gieske and Hanna
Small Cell SMASHERS Fireside Chat: Drs. Gieske and Hanna
In this Facebook Live from June 20, special guests Michael Gieske, MD, St. Elizabeth Cancer Center, and Nasser Hanna, MD, Indiana University School of Medicine, presented "Lung Cancer Screening: Eligibility, Engaging Healthcare Systems, and Impact for Lung Cancer including SCLC."Moderated by Misty Shields, MD, PhD, IU Health, and LUNGevity’s Ann Fish-Steagall, SVP of Patient Services and Health Care Delivery, the monthly Small Cell SMASHERS series highlights the latest discoveries and…
Surviving LMD: Michelle Never Settled for “No”
Surviving LMD: Michelle Never Settled for “No”
Michelle knew what was wrong. She knew the headaches, regular vomiting, ear popping, and “whooshing” sounds in her head were all signs of leptomeningeal disease (LMD). The issue, however, is that LMD is so rare—only diagnosed in 5% of people with cancer—she had to advocate for the testing to prove it.“I called my clinic and said I needed a brain MRI because I think I have LMD. They didn’t want to schedule one, so I said, tell my doctor I’m demanding a brain MRI. I can tell him directly if I…
Small Cell SMASHERS Fireside Chat: Dr. Nagla Karim
Small Cell SMASHERS Fireside Chat: Dr. Nagla Karim
On May 23, special guest Nagla Karim, MD, from the Inova Schar Cancer Institute, spoke with us about the application of subtyping and biomarkers for SCLC.Moderated by Misty Shields, MD, PhD, IU Health, and LUNGevity’s Ann Fish-Steagall, SVP of Patient Services and Health Care Delivery, the monthly Small Cell SMASHERS series highlights the latest discoveries and breakthroughs for SCLC.
Watch HOPE Summit Videos
Watch HOPE Summit Videos
HOPE Summit 2025 was filled with messages of hope, meeting new and hugging old friends, and of course the inspirational and informative sessions that help people live well with lung cancer. For the first time ever, select sessions were recorded for those who weren’t able to attend, and for those who did attend to rewatch what resonated. View the entire collection here or see below for the sessions you want to watch.HOPE Summit 2025 Recorded SessionsKeynote: Breathing Beyond Boundaries…